Tamiflu Safety Will Get FDA Committee Review Nov. 27
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.